Parkinson's Disease Treatment Market

Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022

Report Code: PH 5674 Oct, 2017, by marketsandmarkets.com

[113 Pages Report] The Parkinsonís disease treatment market was valued at USD 3.99 billion in 2016 and expected to grow at a CAGR of 6.1% from 2017 to 2022 to reach USD 5.69 billion in 2022. The carbidopa/levodopa drug class is projected to register highest CAGR during forecast period. The major driving factors for this market include ageing population and government funding for research, growing healthcare awareness.  The base year considered for the study is 2016, and the forecast has been provided for the period between 2018 and 2023.

Market Dynamics

Drivers

  • Growth in ageing population and the associated increase in the prevalence of parkinsonís disease
  • Government funding for research

Restraint

  • Availability of alternative treatments

Opportunities

  • Patent expiry of branded drugs
  • Strong pipeline

The objectives of this study are as follows:

  • To define, describe, and forecast the global Parkinsonís disease therapeutic drugs market by drug class, distribution channel, treatment facility, and region
  • To provide detailed information regarding the major factors influencing market growth (drivers, restraints, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  •  To track and analyze competitive developments such as product launches, agreements, expansions, acquisitions, and other developments in the global Parkinsonís disease therapeutic drugs market

Research Methodology

Top-down and bottom-up approaches were used to estimate and validate the size of the global Parkinsonís disease treatment market and to estimate the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual markets (mentioned in the market segmentation-by drug class, distribution channel, patient care setting, and region) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. Various secondary sources referred to for this research study include publications from government sources such as the white papers; articles from recognized authors; gold standard and silver standard websites, directories, and databases; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations have been used to identify and collect information useful for this extensive commercial study of the Parkinsonís disease treatment market. Primary sources such as experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess prospects of the Parkinsonís disease treatment market. The breakdown of profiles of primaries is shown in the figure below:

Parkinsons Disease Treatment Market

To know about the assumptions considered for the study, download the pdf brochure

Key players operating in the Parkinsonís disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (US), Sun Pharma (India), Wockhardt (India), Dr. Reddyís (India), Intas (India), US WorldMeds (US), Zydus Cadila (India), Cipla (India), Strides (India), 1 A Pharma (India), and Upsher-Smith (US).

Major Market Developments

  • In 2016, ACADIA Pharmaceuticals, Inc. (U.S.) received FDA approval for its NUPLAZID drug
  • In 2016, Sun Pharmaceutical Industries Ltd. (India) entered distribution agreement with Mitsubishi Tanabe Pharma Corporation (Japan) to distribute 14 prescription brands that include Parkinsonís disease drug Parlodel in Japan

Critical questions the report answers:

  • How the market developments of key players impact the overall industry?
  • What are the restraining factors for this market?

Currently, a wide range of treatments is available for alleviating the symptoms of Parkinsonís disease. Medication is the first line therapy for treating the disease; however, they are not effective in all stages of the disease. In the severe stages, medications do not show pharmacological action in relieving disease symptoms. Neurologists perform thalamotomy, pallidotomy, or implant deep brain stimulation (DBS) devices in order to ease symptoms.

Moreover, the focus on gene therapy research has increased. According to the Parkinson's Disease Clinic and Research Center, University of California, US, gene therapy for Parkinsonís disease has shown promising results in phase I studies. Phase II and III studies are currently under progress. Surgical treatments, restriction on the use of medications in severe stages of the disease, and the increased focus on gene therapy research are expected to restrain the demand for therapeutic drugs used in Parkinsonís disease.

Target Audience for this Report:

  • Parkinsonís disease treatment product manufacturers
  • Parkinsonís disease treatment dealers and suppliers
  • Human identification service providers
  • Parkinsonís disease associations
  • Academic institutions
  • Venture capitalists
  • Consulting firms
  • Government bodies

Value Addition for the Buyer:

This report aims to provide insights into the global Parkinsonís disease treatment market. It provides valuable information on the market classification by drug class, distribution channels, and patient care setting. Details on regional markets for these segments have also been presented in this report. In addition, leading players in the market are profiled to understand the strategies undertaken by them to be competitive in this market.

Scope of the Report:

This report categorizes the Parkinsonís disease treatment market into the following segments:

By Drug Class

  • Levodopa/carbidopa
  • Dopamine Receptor Agonists
  • MAO-Inhibitors
  • COMT-inhibitors
  • Anticholinergics
  • Other Drugs

By Distribution Channel

  • Hospital Pharmacies
  • Retailer Pharmacies
  • Online Pharmacies

By Patient Care Setting

  • Hospitals
  • Clinics

By Region

  • North America
    • US
    • Canada
  • Europe
  • Asia
    • China
    • Japan
    • Rest of Asia (RoA)
  • Rest of the World (RoW)

Customization Options:

  • Company Information: Detailed company profiles of five or more market players
  • Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

Parkinsonís disease treatment is used to treat the symptoms of Parkinsonís disease, generally, medication is the first line treatment for this disease. The global Parkinsonís disease treatment market is expected to reach USD 5.69 billion by 2022 from USD 4.24 billion in 2017, at a CAGR of 6.1%. Rising geriatric population and government funding for research on Parkinsonís disease are the driving factors for this market.

The Parkinsonís disease treatment market is segmented on the basis of drug class, distribution channel, patient care setting, and region. On the basis of drug class, the Parkinsonís disease treatment market is segmented into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to account for the largest share of the market in 2017. The growth in this segment is primarily attributed to the potency of the drug.

By distribution channel, the Parkinsonís disease treatment market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. In 2017, the hospital pharmacies segment accounted for the largest share of the market. Increasing number of patient visits to the hospital due to the availability of diagnostic laboratories and presence of skilled neurologists are driving the growth of hospital pharmacies segment.

On the basis of patient care setting, the Parkinsonís disease treatment market is segmented into hospitals and clinics. In 2017, hospitals are expected to account for the largest share of the Parkinsonís disease treatment market. Robust health infrastructure and presence of skilled neurologists are the driving factors for hospital segment.

Parkinsons Disease Treatment Market

By region, the Parkinsonís disease treatment market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by Europe, followed by North America, however, the Asian region is expected to witness the highest growth during the forecast period. Asia is expected to witness the highest CAGR, with the growth in this market centered at Japan, China, and India. The increasing number of generic drug manufacturers and rising aging populaion across are key factors driving the Parkinsonís disease treatment market in Asia. However, availability of alternative treatments is going to restrain this market.

Presence of skilled professional in the hospital care setting drives the grwoth of parkinsons disease treatment market

Hospital

Hospitals segment is estimated to account for the largest share of the Parkinsonís disease treatment market in 2017. This segment includes large, medium-sized, and small hospitals as well as critical care centers. Growth in this market can largely be attributed to the patient visits to hospitals are very high owing to the availability of diagnostic laboratories for diagnosing diseases; and presence of skilled professionals.

Clinics

Clinics, also known as outpatient clinics or ambulatory care clinics, are healthcare facilities where outpatients are treated. In comparison with hospitals, clinics are expected to hold a smaller share of the overall market in the coming years mainly due to the shortage of neurologists in these facilities. In addition, most clinics do not have in-house diagnostic laboratories, owing to which most patients prefer hospitals.

Teva (Israel), AbbVie (US), Boehringer Ingelheim (Germany) Lundbeck (Denmark), Acadia (US), Sun Pharma (India), US WorldMeds (US), Dr. Reddyís (India), are the top players in this market. These companies have a broad product portfolio with comprehensive features and a strong geographical presence.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Parkinson's Disease Treatment Market: Introduction (Page No. - 12)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Markets Covered
           1.2.2 Years Considered for the Study
    1.3 Currency
    1.4 Limitations
    1.5 Stakeholders

2 Parkinson's Disease Treatment Market: Research Methodology (Page No. - 15)
    2.1 Research Data
           2.1.1 Secondary Data
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Key Data From Primary Sources
    2.2 Market Size Estimation
           2.2.1 Bottom-Up Approach
           2.2.2 Top-Down Approach
    2.3 Market Breakdown and Data Triangulation
    2.4 Assumptions for the Study

3 Parkinson's Disease Treatment Market: Executive Summary (Page No. - 23)

4 Parkinson's Disease Treatment Market: Premium Insights (Page No. - 27)
    4.1 Parkinsonís Disease Treatment Market Overview
    4.2 Geographic Analysis: Parkinsonís Disease Treatment Market, By Drug Class
    4.3 Geographic Analysis of the Parkinsonís Disease Treatment Market, By Country
    4.4 Geographic Analysis of the Parkinsonís Disease Treatment Market

5 Parkinson's Disease Treatment Market: Overview (Page No. - 31)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Growth in Aging Population and the Associated Increase in the Prevalence of Parkinsonís Disease
                    5.2.1.2 Government Funding for Research
           5.2.2 Restraints
                    5.2.2.1 Availability of Alternative Treatments
           5.2.3 Opportunities
                    5.2.3.1 Patent Expiry of Branded Drugs
                    5.2.3.2 Strong Drug Pipeline

6 Parkinsonís Disease Treatment Market, By Drug Class (Page No. - 36)
    6.1 Introduction
    6.2 Carbidopa/Levodopa
    6.3 Dopamine Receptor Agonists
    6.4 Mao Inhibitors
    6.5 Comt Inhibitors
    6.6 Anticholinergics
    6.7 Other Drugs

7 Parkinsonís Disease Treatment Market, By Distribution Channel (Page No. - 47)
    7.1 Introduction
    7.2 Hospital Pharmacies
    7.3 Retailer Pharmacies
    7.4 Online Pharmacies

8 Parkinsonís Disease Treatment Market, By Patient Care Setting (Page No. - 52)
    8.1 Introduction
    8.2 Hospitals
    8.3 Clinics

9 Parkinsonís Disease Treatment Market, By Region (Page No. - 57)
    9.1 Introduction
    9.2 Europe
    9.3 North America
           9.3.1 U.S.
           9.3.2 Canada
    9.4 Asia
           9.4.1 Japan
           9.4.2 China
           9.4.3 Rest of Asia
    9.5 Rest of the World

10 Company Profiles (Page No. - 77)
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
     10.1 GSK
     10.2 Merck
     10.3 Novartis
     10.4 Teva
     10.5 Boehringer Ingelheim
     10.6 Impax
     10.7 Abbvie
     10.8 Valeant Pharmaceuticals
     10.9 Lundbeck
     10.10 Sun Pharma
     10.11 Wockhardt
     10.12 Acadia
     10.13 UCB

*Details on Marketsandmarkets View, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments Might Not Be Captured in Case of Unlisted Companies.

11 Appendix (Page No. - 105)
     11.1 Insights of Industry Experts
     11.2 Discussion Guide
     11.3 Knowledge Store: Marketsandmarketsí Subscription Portal
     11.4 Introducing RT: Real-Time Market Intelligence
     11.5 Available Customizations
     11.6 Related Reports
     11.7 Author Details


List of Tables (66 Tables)

Table 1 Global Parkinsonís Disease Treatment Market Summary
Table 2 Ageing Population, By Region, 2015 vs 2030
Table 3 Parkinsonís Disease Treatment Market: List of Pipeline Drugs
Table 4 Parkinsonís Disease Treatment Market, By Drug Class, 2016Ė2022 (USD Million)
Table 5 Carbidopa/Levodopa Market, By Region, 2015Ė2022 (USD Million)
Table 6 North America: Carbidopa/Levodopa Market, By Country, 2015Ė2022 (USD Million)
Table 7 Asia: Carbidopa/Levodopa Market, By Country, 2015Ė2022 (USD Million)
Table 8 Dopamine Receptor Agonists Market, By Region, 2015Ė2022 (USD Million)
Table 9 North America: Dopamine Receptor Agonists Market, By Country, 2015Ė2022 (USD Million)
Table 10 Asia: Dopamine Receptor Agonists Market, By Country, 2015Ė2022 (USD Million)
Table 11 Mao Inhibitors Market, By Region, 2015Ė2022 (USD Million)
Table 12 North America: Mao Inhibitors Market, By Country, 2015Ė2022 (USD Million)
Table 13 Asia: Mao Inhibitors Market, By Country, 2015Ė2022 (USD Million)
Table 14 Comt Inhibitors Market, By Region, 2015Ė2022 (USD Million)
Table 15 North America: Comt Inhibitors Market, By Country, 2015Ė2022 (USD Million)
Table 16 Asia: Comt Inhibitors Market, By Country, 2015Ė2022 (USD Million)
Table 17 Anticholinergics Market, By Region, 2015Ė2022 (USD Million)
Table 18 North America: Anticholinergics Market, By Country, 2015Ė2022 (USD Million)
Table 19 Asia: Anticholinergics Market, By Country, 2015Ė2022 (USD Million)
Table 20 Other Drugs Market, By Region, 2015Ė2022 (USD Million)
Table 21 North America: Other Drugs Market, By Country, 2015Ė2022 (USD Million)
Table 22 Asia: Other Drugs Market, By Country, 2015Ė2022 (USD Million)
Table 23 Parkinsonís Disease Treatment Market, By Distribution Channel, 2015Ė2022 (USD Million)
Table 24 Parkinsonís Disease Treatment Market for Hospital Pharmacies, By Region, 2015Ė2022 (USD Million)
Table 25 North America: Parkinsonís Disease Treatment Market for Hospital Pharmacies, By Country, 2015Ė2022 (USD Million)
Table 26 Parkinsonís Disease Treatment Market for Retail Pharmacies, By Region, 2015Ė2022 (USD Million)
Table 27 North America: Parkinsonís Disease Treatment Market for Retailer Pharmacies, By Country, 2015Ė2022 (USD Million)
Table 28 Parkinsonís Disease Treatment Market for Online Pharmacies, By Region, 2015Ė2022 (USD Million)
Table 29 North America: Parkinsonís Disease Treatment Market for Online Pharmacies, By Country, 2015Ė2022 (USD Million)
Table 30 Parkinsonís Disease Treatment Market, By Patient Care Setting, 2015Ė2022 (USD Million)
Table 31 Parkinsonís Disease Treatment Market for Hospitals, By Region, 2015Ė2022 (USD Million)
Table 32 North America: Parkinsonís Disease Treatment Market for Hospitals, By Country, 2015Ė2022 (USD Million)
Table 33 Asia: Parkinsonís Disease Treatment Market for Hospitals, By Country, 2015Ė2022 (USD Million)
Table 34 Parkinsonís Disease Treatment Market for Clinics, By Region, 2015Ė2022 (USD Million)
Table 35 North America: Parkinsonís Disease Treatment Market for Clinics, By Country, 2015Ė2022 (USD Million)
Table 36 Asia: Parkinsonís Disease Treatment Market for Clinics, By Country, 2015Ė2022 (USD Million)
Table 37 Global Parkinsonís Disease Treatment Market, By Region, 2015Ė2022 (USD Million)
Table 38 Europe: Parkinsonís Disease Treatment Market, By Drug Class, 2015Ė2022 (USD Million)
Table 39 Europe: Parkinsonís Disease Treatment Market, By Distribution Channel, 2015Ė2022 (USD Million)
Table 40 Europe: Parkinsonís Disease Treatment Market, By Patient Care Setting, 2015Ė2022 (USD Million)
Table 41 North America: Parkinsonís Disease Treatment Market, By Country, 2015Ė2022 (USD Million)
Table 42 North America: Parkinsonís Disease Treatment Market, By Drug Class, 2015Ė2022 (USD Million)
Table 43 North America: Parkinsonís Disease Treatment Market, By Distribution Channel, 2015Ė2022 (USD Million)
Table 44 North America: Parkinsonís Disease Treatment Market, By Patient Care Setting, 2015Ė2022 (USD Million)
Table 45 US: Parkinsonís Disease Treatment Market, By Drug Class, 2015Ė2022 (USD Million)
Table 46 US: Parkinsonís Disease Treatment Market, By Distribution Channel, 2015Ė2022 (USD Million)
Table 47 US: Parkinsonís Disease Treatment Market, By Patient Care Setting, 2015Ė2022 (USD Million)
Table 48 Canada: Parkinsonís Disease Treatment Market, By Drug Class, 2015Ė2022 (USD Million)
Table 49 Canada: Parkinsonís Disease Treatment Market, By Distribution Channel, 2015Ė2022 (USD Million)
Table 50 Canada: Parkinsonís Disease Treatment Market, By Patient Care Setting, 2015Ė2022 (USD Million)
Table 51 Asia: Parkinsonís Disease Treatment Market, By Country, 2015Ė2022 (USD Million)
Table 52 Asia: Parkinsonís Disease Treatment Market, By Drug Class, 2015Ė2022 (USD Million)
Table 53 Asia: Parkinsonís Disease Treatment Market, By Distribution Channel, 2015Ė2022 (USD Million)
Table 54 Asia: Parkinsonís Disease Treatment Market, By Patient Care Setting, 2015Ė2022 (USD Million)
Table 55 Japan: Parkinsonís Disease Treatment Market, By Drug Class, 2015Ė2022 (USD Million)
Table 56 Japan: Parkinsonís Disease Treatment Market, By Distribution Channel, 2015Ė2022 (USD Million)
Table 57 Japan: Parkinsonís Disease Treatment Market, By Patient Care Setting, 2015Ė2022 (USD Million)
Table 58 China: Parkinsonís Disease Treatment Market, By Drug Class, 2015Ė2022 (USD Million)
Table 59 China: Parkinsonís Disease Treatment Market, By Distribution Channel, 2015Ė2022 (USD Million)
Table 60 China: Parkinsonís Disease Treatment Market, By Patient Care Setting, 2015Ė2022 (USD Million)
Table 61 RoA: Parkinsonís Disease Treatment Market, By Drug Class, 2015Ė2022 (USD Million)
Table 62 RoA: Parkinsonís Disease Treatment Market, By Distribution Channel, 2015Ė2022 (USD Million)
Table 63 RoA: Parkinsonís Disease Treatment Market, By Patient Care Setting, 2015Ė2022 (USD Million)
Table 64 RoW: Parkinsonís Disease Treatment Market, By Drug Class, 2015Ė2022 (USD Million)
Table 65 RoW: Parkinsonís Disease Treatment Market, By Distribution Channel, 2015Ė2022 (USD Million)
Table 66 RoW: Parkinsonís Disease Treatment Market, By Patient Care Setting, 2015Ė2022 (USD Million)


List of Figures (33 Figures)

Figure 1 Global Parkinsonís Disease Treatment Market
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Parkinsonís Disease Treatment Market: Bottom-Up Approach
Figure 5 Parkinsonís Disease Treatment Market: Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Global Parkinsonís Disease Treatment Market, By Drug Class, 2017 vs 2022
Figure 8 Global Parkinsonís Disease Treatment Market, By Distribution Channel, 2017 vs 2022
Figure 9 Global Parkinsonís Disease Treatment Market, By Patient Care Setting, 2017 vs 2022
Figure 10 Global Parkinsonís Disease Treatment Market, By Region, 2017 vs 2022
Figure 11 Increasing Prevalence of Parkinsonís Disease to Drive the Growth of the Parkinsonís Disease Treatment Market
Figure 12 Carbidopa/Levodopa Segment and Japan to Account for the Largest Market Share in 2017
Figure 13 Japan to Register the Highest CAGR During the Forecast Period
Figure 14 Europe to Register the Highest Markest Share During the Forecast Period
Figure 15 Parkinsonís Disease Treatment Market: Drivers, Restraints, and Opportunities
Figure 16 Hospital Pharmacies to Continue to Dominate the Parkinsonís Disease Treatment Market During the Forecast Period
Figure 17 Hospitals Segment to Dominate the Parkinsonís Disease Treatment Market During the Forecast Period
Figure 18 Parkinsonís Disease Treatment Market: Geographic Snapshot (2017-2022)
Figure 19 North America: Market Snapshot
Figure 20 Asia: Market Snapshot
Figure 21 GSK .: Company Snapshot
Figure 22 Merck: Company Snapshot
Figure 23 Novartis: Company Snapshot
Figure 24 Teva : Company Snapshot
Figure 25 Boehringer Ingelheim: Company Snapshot
Figure 26 Impax: Company Snapshot
Figure 27 Abbvie.: Company Snapshot
Figure 28 Valeant: Company Snapshot
Figure 29 Lundbeck: Company Snapshot
Figure 30 Sun Pharma: Company Snapshot
Figure 31 Wockhardt: Company Snapshot
Figure 32 Acadia.: Company Snapshot
Figure 33 UCB: Company Snapshot


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
PH 5674
Published ON
Oct, 2017
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Parkinson's Disease Treatment Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved